[Intocell: Patent Concerns Create Buying Opportunity Amid Volatility]

Intocell is showing strong performance. It appears that a securities firm's analysis, which suggests that the recent drop in share price due to patent issues has created a buying opportunity, is influencing the stock price.

As of 1:55 p.m. on July 30, Intocell is trading at 27,100 won, up 9.72% from the previous trading day.

Kim Seona, a researcher at Hana Securities, explained, "Intocell has only been validated up to the preclinical stage, so an evaluation of human safety is still required," and added, "Through various animal experiments, both safety and cancer-specific effects have been confirmed."

She continued, "The company is still maintaining its joint development relationship with Samsung Bioepis," and added, "While experiencing the limitations of payloads, the characteristic of having no restrictions on functional groups in linker conjugation could potentially make it a key solution in the ADC industry."

She emphasized, "The current noise surrounding patent issues, which may ultimately prove to be insignificant, could represent the best buying opportunity." She also stated, "I hope that the atmosphere will turn around in the second half of this year with the announcement of new partnerships or the unveiling of new drug pipelines by existing partners." Additionally, she assessed, "I believe this is a company with strong capabilities," and advised, "I will continue to watch it closely with interest."